MediciNova
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- -
- Market Cap
- $71.6M
- Introduction
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
Clinical Trials
17
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (17 trials with phase data)• Click on a phase to view related trials
MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
- Conditions
- Non-Alcoholic Fatty Liver DiseaseDiabetes Mellitus, Type 2Hypertriglyceridemia
- Interventions
- Drug: MN-001 placebo
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 40
- Registration Number
- NCT05464784
- Locations
- 🇺🇸
Pinnacle Clinical Research at South Texas Research Institute, Edinburg, Texas, United States
🇺🇸Jubilee Clinical Research, Inc., Las Vegas, Nevada, United States
Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 34
- Registration Number
- NCT04429555
- Locations
- 🇺🇸
Denver Health and Hospital Authority, Denver, Colorado, United States
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
- First Posted Date
- 2019-08-15
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 230
- Registration Number
- NCT04057898
- Locations
- 🇺🇸
University of California, Orange, California, United States
🇺🇸Mayo Clinic, Jacksonville, Florida, United States
🇺🇸Augusta University, Augusta, Georgia, United States
Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers
- First Posted Date
- 2019-08-13
- Last Posted Date
- 2020-07-15
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 12
- Registration Number
- NCT04054206
- Locations
- 🇺🇸
Collaborative Neuroscience Network, Garden Grove, California, United States
Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma
- Conditions
- Newly Diagnosed GlioblastomaRecurrent GlioblastomaGBMGlioblastoma
- Interventions
- First Posted Date
- 2018-12-20
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 64
- Registration Number
- NCT03782415
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Prev
- 1
- 2
- 3
- 4
- Next
News
First Patient Enrolled in NIH-Funded Expanded Access Program for MN-166 in Advanced ALS
MediciNova has enrolled the first patient in an NIH-funded Expanded Access Program trial evaluating MN-166 (ibudilast) in approximately 200 ALS patients who are ineligible for the ongoing Phase 2/3 COMBAT-ALS trial.
MediciNova's Ibudilast Shows Promise in ALS Trial: Interim Analysis Reveals Strong Correlations
MediciNova's COMBAT-ALS Phase 2/3 trial of MN-166 (ibudilast) in ALS shows positive correlations between 6-month and 12-month data for key metrics.
Ibudilast Expanded Access Program for ALS Patients Managed by Widetrial
Widetrial will manage the physician network for an expanded access program (EAP) providing ibudilast (MN-166) to ALS patients ineligible for clinical trials.
MediciNova's Ibudilast (MN-166) Shows Promise in ALS Treatment: Phase 2/3 Trial Update
MediciNova presented an update on its Phase 2/3 COMBAT-ALS trial of MN-166 (ibudilast) for amyotrophic lateral sclerosis (ALS) at the 2024 Annual NEALS Meeting.
MediciNova's Ibudilast (MN-166) Shows Promise in COMBAT-ALS Trial: Interim Analysis to be Presented at International Symposium
MediciNova's MN-166 (ibudilast) abstract, detailing the COMBAT-ALS trial for ALS treatment, has been accepted for a poster presentation.